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Neutrophil extracellular traps (NET) induce a procoagulant responselinking inflammation and thrombosis. Low levels of miR-146a, abrake of inflammatory response, are involved in higher risk of car-
diovascular events, but the mechanisms explaining how miR-146a exerts
its function remain largely undefined. The aim of this study was to explore
the impact of miR-146a deficiency in NETosis both in sterile and non-ster-
ile models in vivo, and to investigate the underlying mechanism. Two mod-
els of inflammation were used: (i) Ldlr-/- mice transplanted with bone mar-
row from miR-146a-/- or wild-type mice were fed a high-fat diet, generating
an atherosclerosis model; and (ii) an acute inflammation model was gen-
erated by injecting lipopolysaccharide (1 mg/kg) into miR-146a-/- and wild-
type mice. miR-146a deficiency increased NETosis in both models.
Accordingly, miR-146a-/- mice showed significantly reduced carotid occlu-
sion time and elevated levels of NET in thrombi following FeCl3-induced
thrombosis. Infusion of DNAse I abolished arterial thrombosis in both WT
and miR-146a-/- mice. Interestingly, miR-146a-deficient mice have aged,
hyperreactive and pro-inflammatory neutrophils in their circulation which
are more prone to form NET independently of the stimulus. Furthermore,
we demonstrated that patients with community-acquired pneumonia
with reduced miR-146a levels associated with the T variant of the func-
tional rs2431697 had an increased risk of cardiovascular events due, in
part, to an increased generation of NET.
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ABSTRACT
Introduction
Neutrophils play a crucial role in immunity and injury repair but also contribute
to the development of several thrombo-inflammatory diseases.1 The pathophysio-
logical role of neutrophils has become more evident following the discovery of neu-
trophil extracellular traps (NET).2 NET are large web-like structures released upon
neutrophil activation, comprising a matrix of DNA and histones which are decorat-
ed with antimicrobial proteins, such as myeloperoxidase or neutrophil elastase
(NE).3 These structures were first identified as a novel innate defense mechanism;3
however, NET also promote thrombosis through activation of platelets and the
coagulation cascade.4 Therefore, NET interconnect immunity, inflammation, and
thrombosis within a physiological process known as immunothrombosis.5 Thus,
uncontrolled or aberrant activation of immunothrombosis
promotes thrombotic pathologies such as stroke, myocar-
dial infarction, deep vein thrombosis, or disseminated
intravascular coagulation during sepsis.5,6
A large variety of infectious and sterile inflammatory
stimuli have been described as triggers of NETosis.
Interestingly, their consequences on neutrophil activation
vary depending on the nature and duration of the stimu-
lus.7 Two mechanisms resulting in NET formation have
been described: lytic and vital NETosis.8 Specific micro-
organisms or lipopolysaccharides (LPS) induce vital
NETosis directly or indirectly through toll-like receptors
(TLR), via a TLR4-activated platelet interaction, by an oxi-
dant-independent mechanism.9,10 This strategy aims to
limit the spread of bacteria and keeps neutrophils alive for
further functions.8 Alternatively, lytic NETosis can be
induced by diverse sterile agonists such as phorbol 12-
myristate 13-acetate,3,11 cholesterol crystals11 or cytokines
(interleukin-6,12 interleukin-8,3,13 interferon-α14). This drives
NADPH oxidase activation via protein kinase C and Raf-
MEK-ERK, which generates reactive oxygen species (ROS)
inducing neutrophil death.15
MicroRNA (miRNA or miR) are a family of small non-
coding RNA that regulate gene expression.16 Since their
discovery, miRNA have been implicated as key modula-
tors of numerous physiological and pathological process-
es.17-20 In particular, miR-146a directly mediates thrombo-
inflammatory processes as: (i) it inhibits several pro-
inflammatory elements of the TLR-NF (nuclear factor)-κB
pathway21,22 and (ii) it is predominantly expressed in cells
that promote thrombogenesis (monocytes/macrophages,
platelets, neutrophils, and endothelial cells).23,24 Our group
demonstrated that reduced levels of miR-146a, guided by
the T variant of the functional miR-SNP rs2431697, are
predictors of adverse cardiovascular events in patients
with atrial fibrillation.24 Interestingly, in vitro activation of
rs2431697 TT neutrophils exacerbated NET release in
accordance with elevated plasma NE levels found in T car-
riers, who also had a higher risk of adverse cardiovascular
events.25 Overall, our data suggest that miR-146a is crucial-
ly involved in linking inflammation, thrombosis, and
NETosis. However, the role of miR-146a in
immunothrombosis and NETosis is unknown. Here, we
investigated the involvement of miR-146a in NET forma-
tion leading to arterial thrombosis in both sterile and non-
sterile inflammatory murine models. Thus, we character-
ized the neutrophil phenotype to explain the exacerbated
NETosis. Finally, we evaluated the association between
low miR-146a levels, NETosis markers and the occurrence




Irradiation and bone marrow (BM) transplantation were per-
formed as previously described.26 Briefly, Ldlr-/-mice were irradiat-
ed and transplanted with BM cells obtained from wild-type (WT)
or miR-146a-/- mice. After 4 weeks on a standard diet, transplant-
ed mice were fed an atherogenic diet for 8 weeks. Blood was col-
lected from the facial vein into 3.2% citrate and plasma samples
were stored at -80ºC until analysis. Heart and aorta were extract-
ed from euthanized mice after in situ perfusion with phosphate-
buffered saline and fixed with 4% paraformaldehyde overnight
at 4ºC. Tissue was embedded in paraffin and cross-sections from
the aortic root were made.
Endotoxemia model
WT and miR-146a-/-mice were injected intraperitoneally with a
sublethal dose of LPS (1 mg/kg) (E. coli 0111/B4, Sigma-Aldrich,
Madrid, Spain). For morphological analysis, lungs were fixed
with 4% paraformaldehyde overnight at 4ºC, embedded in
paraffin and sectioned. Lung damage was evaluated in one sec-
tion/mouse using a semi-quantitative score via a blind method
following the pathologist’s criteria.
Ferric chloride-induced arterial thrombosis
Animals were anesthetized by intraperitoneal injection
(xylazine hydrochloride 10 mg/kg + ketamine hydrochloride 100
mg/kg). The carotid artery was isolated and the injury was gen-
erated by applying a piece of filter paper (5x1 mm) (GE
Healthcare Whatman 1003917, Fisher, Madrid, Spain) soaked in
a 7.5% ferric chloride (FeCl3) solution for 2 min (Sigma-Aldrich,
Madrid Spain). After washing the arterial surface with saline
solution and removing residual FeCl3, a Doppler ultrasound flow
probe (Model 0.5 PSB, Transonic Systems, Ithaca, NY, USA) was
applied. The probe was connected to a flow meter (Model
TS420, Transonic Systems, Ithaca, NY, USA) that continuously
registered the blood flow. Occlusion time was defined as the
time elapsed from the withdrawal of FeCl3 to the lack of blood
flow (≤ 0.01 mL/min) for at least 3 consecutive minutes.
Experiments were stopped after 30 min if no occlusion occurred.
For the experiments with DNase I, mice were injected intra-
venously (tail vein) with 10 mg of Pulmozyme® (Roche Farma,
Madrid, Spain) diluted in saline, 15 min before FeCl3 treatment.
Patients and controls
The study (NEUMONAC study #2011/0219 [05/07/2011]) was
approved by the Ethical Committee (ceic@iislafe.es) of our insti-
tution and performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki and its subsequent
amendments. Consecutive patients admitted with community-
acquired pneumonia (CAP) were included from October 2015 to
June 2018 at Hospital Universitario y Politécnico La Fe (Valencia,
Spain). The patients’ details are provided in the Online
Supplementary Methods. 
Healthy subjects were randomly selected among blood donors
from our Transfusion Center and gave their informed consent to
enrollment into the study.
Statistical analysis
All statistical analyses were conducted using GraphPad Prism
3.8 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 22.0
for Windows (SPSS, Inc., Chicago, IL, USA). Differences between
two groups were assessed by an unpaired Student t-test or Mann-
Whitney U test, where appropriate. For multiple comparisons,
one-way analysis of variance on ranks with the Bonferroni post-
hoc test was used. Data are shown as mean ± standard error of
mean or as median (95% confidence interval), as appropriate. A
P-value <0.05 was considered statistically significant.
Further details on the materials and methods are available in
the Online Supplementary Methods.
Results
miR-146a deficiency promotes NET formation in 
an atherosclerosis model
Previous data from our laboratory demonstrated that
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miR-146a deficiency upregulates NETosis in both murine
and human in vitro models.25 Thus, we aimed to extrapo-
late this finding to different in vivo models. We first uti-
lized an atherosclerosis mouse model previously generat-
ed by our group.26 Briefly, Ldlr-/- mice were transplanted
with BM from miR-146a-/- or WT animals and fed a high-
fat diet for 8 weeks (Figure 1A). As reported, transplant
efficiency, body weight, circulating blood cell counts,
plasma lipid profile, and atherosclerotic burden (athero-
ma, lesion, and necrotic core areas) were similar between
the experimental groups.26 No differences were found in
cell-free (cf)DNA and NE plasma levels between the two
groups of mice before they were fed the high-fat diet
(data not shown). As expected, after 8 weeks of the athero-
genic diet, notable differences in NET components
between the two groups were observed. As shown in
Figure 1B, plasma cfDNA levels were significantly higher
in Ldlr-/- BM miR-146a-/- mice than in Ldlr-/- BM WT litter-
mates (348.1 ± 73.0 vs. 177.3 ± 39.4 ng/mL, respectively;
P<0.05). Similarly, plasma NE was almost 2-fold higher in
BM miR-146a-/- mice than in BM WT mice (228.6 ± 32.6
vs. 113.0± 14.2 ng/mL, respectively; P<0.05) (Figure 1C).
In addition, immunofluorescence analysis of aortic valves
revealed that, although intact neutrophils were found in
both cases (Online Supplementary Figure S1), there were
substantial differences in the size and the amount of NET.
DNA, and NE, and H2B staining revealed an increase of
large NET in the atherosclerotic lesions and adhered to
the vascular wall of BM miR-146a-/-mice compared to BM
WT mice, in which we only identified scattered NET
throughout all the sections (Figure 1D). Quantification of
NET in whole sections within aortic roots confirmed that
miR-146a-/- mice had more NET than had WT mice (ICorr
values 0.78 ± 0.09 vs. 0.53 ± 0.07, respectively; P<0.01)
(Figure 1E). In addition, zooming within NETotic areas
demonstrated that H2B and NE co-localization was near
to 100% (R=0.97; Costes P-value=1), in contrast to the
low co-localization found in intact neutrophils (R=0.13;
Costes P-value=1) (Figure 1F, Online Supplementary Movies
S1 and S2). Collectively, these results demonstrated a role
for miR-146a in NET formation during the process of ath-
erosclerosis.
miR-146a mediates NETosis and lung damage 
in an lipopolysaccharide-induced, sublethal model 
of inflammation
The molecular mechanisms leading to NETosis differ
depending on the triggering stimulus.7 In order to investi-
gate whether miR-146a may link different pathways pro-
voking NETosis, we next examined the implication of
miR-146a on NET formation using a non-sterile inflam-
matory mouse model generated by sublethal injection of
LPS (1 mg/kg) for 4 h and 24 h. As expected, there was a
significant progressive reduction in circulating leukocyte
and platelet counts following induction of endotoxemia,
although no relevant differences between miR-146a-/- and
WT animals (Online Supplementary Figure S2) were
observed. As shown in Figure 2, basal plasma NET mark-
ers were similar between miR-146a-/- and WT mice.
However, following LPS administration at 4 h and 24 h,
plasma cfDNA levels were higher in miR-146a-/-mice than
in WT mice, with the difference being statistically signif-
icant at 4 h (1653.0 ± 216.5 vs. 845.6 ± 294.4 ng/mL,
respectively; P<0.01) (Figure 2A). Similarly, LPS injection
resulted in significantly higher levels of plasma NE in miR-
146a-/- mice when compared to WT mice, after 4 h
(1671.3 ± 95.6 vs. 1206.1 ± 99.2 ng/mL, respectively;
P<0.01) and 24 h (2458.0 ± 57.1 vs. 1524.6 ± 61.2 ng/mL,
respectively; P<0.001) (Figure 2B). Higher NETosis in miR-
146a-/- mice following LPS challenge was confirmed by
western blotting. Plasma citrullinated histone 3 (citH3)
levels were higher in miR-146a-/- mice than in WT mice at
both 4 h and 24 h (Figure 2C). Finally, additional inflam-
matory and coagulation markers were analyzed. LPS-
dependent ROS production at 24 h was significantly
higher compared with basal levels only in miR-146a-/-
mice (178%; P<0.05) (Figure 2D). Additionally, the
amounts of thrombin-antithrombin (TAT) complexes
were significantly greater 4 h after LPS injection than at
baseline only in miR-146a-/- mice (43%; P<0.05) (Figure
2E).
Although all mice indistinctly survived sublethal LPS
injection, we explored whether LPS challenge could dif-
ferentially damage mice lungs. Staining of lung sections
showed a notable increase of reticulin in samples from
miR-146a-/- mice compared with their WT littermates
after 4 h of LPS (Figure 2F). According to the pathologist’s
criteria, the analysis showed that both reticulin score and
global lung injury were increased in miR-146a-/-mice com-
pared to WT mice (Figure 2G). Therefore, miR-146a-defi-
cient mice had higher NETosis, oxidative stress and acti-
vation of coagulation and consequently, greater lung
damage after LPS injection.
miR-146a deficiency confers an aged, overactive, 
and pro-inflammatory phenotype to neutrophils
Although neutrophils have been considered to be a rel-
atively homogeneous population, evidence demonstrat-
ing their heterogeneity is emerging.1 To investigate
whether the increased ability of miR-146a-/- neutrophils
to form NET in the above-mentioned models was related
to a particular phenotype determined by miR-146a defi-
ciency, we explored the aged/activated state of neu-
trophils by flow cytometry. miR-146a deficiency did not
alter the total percentage of neutrophils in the circulation
(Online Supplementary Figures S2 and S3). Analysis of neu-
trophil surface markers revealed that miR-146a-/- neu-
trophils exhibited significantly higher levels of Cxcr4 and
CD11b, and lower levels of CD62L than WT neutrophils
(Figure 3A). Our results also showed that neutrophils
from miR-146a-/- mice had significantly lower Cxcr1 lev-
els than neutrophils from their WT littermates (Figure
3B), suggesting an additional pro-inflammatory ability
for the miR-146a-/- neutrophil phenotype.27-29 Tlr4 has
been implicated in the process of aging30 and is a target of
miR-146a.31 Thus, we measured and compared its levels
in miR-146a-/- and WT neutrophils from whole blood and
found that, as described before, aged neutrophils
(defined by Cxcr4high and CD62Llow surface expression)
expressed higher levels of Tlr4 than the rest.
Interestingly, aged miR-146-/- neutrophils expressed sig-
nificantly more Tlr4 than aged WT neutrophils (Figure
3C). Moreover, miR-146a deficiency in isolated neu-
trophils produced significantly higher ROS levels (Figure
3D) and elevated oxygen consumption rate (Figure 3E) at
basal state compared with those in neutrophils from WT
mice. Thus, miR-146a deficiency seems to promote
aging and hyperreactivity to neutrophils, a pro-inflam-
matory phenotype that could contribute to the exacer-
bated NETosis of these cells.
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Figure 1. miR-146a deficiency enhances neutrophil extracellular trap formation in atherosclerosis. (A) Ldlr-/- mice were transplanted with bone marrow (BM) from
miR-146a-/- or wild-type (WT) mice. After 4 weeks of recovery, mice were fed a high-fat diet for 8 weeks. Blood and aortic tissues were extracted for quantification of
the formation of neutrophil extracellular traps (NET) (n=10-12/group). (B) Plasma cell-free (cf)DNA was measured using Sytox Green. (C) Plasma neutrophil elastase
(NE) activity was quantified by enzyme-linked immunosorbent assay. (D) Representative confocal microscopy images of an aortic valve leaflet, an atherosclerotic area,
and a NET detail from Ldlr-/- BM WT, and  Ldlr-/- BM miR-146a-/ mice immunostained for DNA (DAPI, blue), NE (green), and H2B (red). The dashed yellow line denotes
an atherosclerotic lesion (L) boundary; the lumen (Lu), and valves (V) are also marked. White arrowheads point to NET. (E) NET quantification in aortic valve sections
from Ldlr-/- BM WT, and Ldlr-/- BM miR-146a-/- mice performed with the Colocalization Colormap Fiji plugin. The correlation index (ICorr) represents the fraction of pos-
itively correlated (co-localized) H2B and NE pixels in one representative section per mouse in six WT and six miR-146a-/- BM-transplanted Ldlr-/- mice. (F) Fluorescence
intensity plots of H2B and NE in a region of interest (yellow line) of a NET and a neutrophil found in the aortic valve from a Ldlr-/- BM miR-146a-/- and a Ldlr-/- BM WT
mouse, respectively. The correlation of H2B and NE fluorescence intensity was determined using the Pearson correlation coefficient and Costes method. In the
Pearson correlation test, the R value ranges between -1 and 1, with 1 being a perfect correlation, 0 no linear correlation, and −1 a perfect negative linear correlation.
Costes analysis compares pixel correlation for no-randomized with randomized images and calculates significance. The Costes P-value was 1 in both cases, indicating
that the probability of random images correlating to real images is 0. P-value calculations were performed using the Mann-Whitney U test. Data represent mean ±
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Figure 2. miR-146a deficiency medi-
ates NETosis in endotoxemia. miR-
146a-/- and wild-type (WT) mice were
injected intraperitoneally with a sub-
lethal dose of lipopolysaccharide (LPS)
(1 mg/kg). Plasma markers of neu-
trophil extracellular traps (NET) were
measured 4 h and 24 h after LPS
treatment (n=9/group). (A) Cell-free
(cf)DNA levels were quantified by Sytox
Green. (B) Neutrophil elastase (NE)
levels were measured by enzyme-
linked immunosorbent assay (ELISA).
(C) Citrilluniated histone 3 (CitH3)
plasma levels were analyzed by west-
ern blot. (D) Reactive oxygen species
(ROS) were quantified by fluorometry
24 h after treatment with LPS. (E)
Thrombin-antithrombin (TAT) complex
levels were detected by ELISA 4 h after
LPS treatment. (F) Morphology of
lungs from WT and miR-146a-/- mice
after LPS stimulation. Lung sections
from WT and miR-146a-/- mice treated
4 h with LPS (1 mg/kg) were stained
for reticulin (n=9/group) to observe tis-
sue structure and global injury.
Representative images of reticulin
staining from WT and miR-146a-/- lungs
after LPS at 20x and 40x magnifica-
tion. (G) Semi-quantitative analysis for
reticulin and global lung damage
according to the pathologist’s criteria.
One section/mouse was scored in a
blinded fashion into four grades from 0
to 3 (0=normal, 1=mild, 2=moderate,
3=severe). P-value calculations were
performed using one-way analysis of
variance on ranks with the Bonferroni
post-hoc test or the Mann-Whitney U
test, where appropriate. Data repre-
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Figure 3. miR-146a determines neutrophil pheno-
type. (A) Flow cytometry analysis of CD11b, CD62L,
and Cxcr4 (P<0.05 for all markers) on neutrophils
(Ly6G-positive population) from blood of wild-type
(WT) and miR-146a-/- mice (n=6 mice in both
groups). Contour plots from flow cytometry analysis
of CD62L and CD11b on neutrophils from a repre-
sentative WT mouse and an miR-146a-/- mouse
(bottom left panel). Comparison of Cxcr4 expres-
sion between WT and miR-146a-/- representative
mice (bottom right panel). (B) Flow cytometry analy-
sis of Cxcr1 on neutrophils from blood of WT and
miR-146a-/- mice (left panel; n=5 mice in both
groups; P<0.01). Comparison of Cxcr1 expression
on a representative mouse with each genotype
(right panel). (C) Tlr4 levels were measured in
Cxcr4high and CD62Llow (aged) neutrophil subpopula-
tion versus the rest (n=6 mice in both groups;
P<0.05). Contour plots from flow cytometry analysis
of CD62L and Cxcr4 on peripheral blood pool neu-
trophils from six WT and six miR-146a-/- mice (right
panel). (D) Bone marrow (BM) isolated neutrophils
were incubated with 10 mM H2DCFDA for 30 min at
37°C and analyzed by flow cytometry (n=3 mice in
both groups). (E) BM neutrophils were seeded on
the plate and the oxygen consumption rate (OCR)
was measured by a Seahorse Analyzer. (mean ±
standard deviation, n=3 mice for each group, sam-
ples in quadruplicate). Statistical analyses between
groups of mice were performed using the Mann-
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Figure 4. miR-146a deficiency accelerates carotid thrombotic occlusion. (A) Mouse model of FeCl3-induced carotid arterial thrombosis. The carotid artery from wild-
type (WT) and miR-146a-/- mice was isolated and exposed to 7.5% FeCl3 for 2 min (WT n=24, miR-146a-/- n=17). A Doppler ultrasound flow probe registered the blood
flow continuously. (B) Basal blood flow. (C) Time to carotid thrombotic occlusion. (D) Alternatively, WT (n=7) and miR-146a-/- (n=7) mice were treated with DNase I (10
mg, i.v.) 15 min before vessel injury and the carotid occlusion time was measured for a maximum of 30 min. (E) Representative images of neutrophil extracellular
traps (citrullinated histone 3 [citH3]-positive nuclei) in the carotid thrombi from WT and miR-146a-/- mice analyzed by immunofluorescence. For each genotype the
upper row shows the complete cross-section of the thrombosed carotid artery (bar corresponds to 100 mm) and the lower row a higher magnification of the artery
wall (bar corresponds to 20 mm) and the detail of a neutrophil (bar corresponds to 5 mm) (F-H) Quantification of total infiltrated nucleated cells, citH3-positive cells
and the ratio of total nucleated to citH3-positive cells in the thrombi and the adventitial layer of carotid sections from WT and miR-146a-/- mice (n=10/group). P-value
calculations were performed using the unpaired Student t-test and Mann-Whitney U-test. Data represent mean ± standard error of mean, *P<0.05.
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Loss of miR-146a accelerates time to carotid 
thrombotic occlusion by increasing NET release
Thus, we hypothesized that under a thrombotic stimu-
lus, these neutrophils may favor the production of NET,
thereby strongly contributing to thrombosis. To test this
hypothesis, we induced carotid endothelial injury with
FeCl3 in miR-146a-/- and WT mice (Figure 4A) and deter-
mined time to arterial occlusion. Although basal blood
flow was similar between the two groups of animals
(Figure 4B), miR-146a-/- mice showed a significant reduc-
tion in time to occlusion compared to the time in WT lit-
termates (374.5 ± 21.15 vs. 452.5 ± 26.14 s, respectively;
P<0.05) (Figure 4C). The occlusion times of WT and miR-
146a-/- mice were similar upon treatment with DNAse I
(Figure 4D). Thus, DNAse I treatment abolished arterial
occlusion, supporting the concept that NET are essential
for thrombus formation and stability upon FeCl3 damage.
To further analyze the association between thrombosis
and NETosis, thrombi within carotids were isolated and
immunofluorescence for citH3 was performed. FeCl3-
induced injury promoted similar infiltration of nucleated
cells in both groups (Figure 4E-F); however, the number of
DNA-citH3-positive cells within the carotid thrombi was
significantly higher in miR-146a-/- mice than in WT ones
(19.3 ± 3.3 vs. 10.0 ± 3.6 cells, respectively; P<0.05)
(Figure 4G). The ratio of citH3-positive to total nucleated
cells found in the thrombi of carotid sections was signifi-
cantly higher in miR-146a-/- mice than in WT mice (Figure
4H, Online Supplementary Figure S4).
Of note, no relevant differences in F12 coagulation fac-
tor, recently implicated in NETosis,32 was observed
between the two groups (data not shown). Thus, miR-146a
deficiency may accelerate vessel occlusion due, in part, to
increased NETosis associated with the presence of hyper-
reactive neutrophils.
Low miR-146a levels in patients with 
community-acquired pneumonia are associated with
an increased risk of cardiovascular events
In order to test the clinical impact of our in vivo results,
we recruited 259 patients with CAP with a 30-day fol-
low-up period. Online Supplementary Table S1 shows the
demographic and clinical characteristics of all 259
patients, as well as the frequencies and distribution of the
rs2431697 genotype. We found no significant differences
between the main cardiovascular risk factors and geno-
type (Online Supplementary Table S1). In addition, both
Sepsis-related Organ Failure Assessment (SOFA) score
and neutrophil count at entry were similar in all patients
independently of their genotype (Online Supplementary
Table S1). One hundred and twelve plasma samples were
available for DNA-citH3 measurement. From these, 81
(72.3%) were considered as positive (optical density [OD]
values >0.200, the maximum OD value yielded for 30
healthy controls) (Online Supplementary Figure S5, Online
Supplementary Table S2). As described for septic patients,
plasma levels of DNA-citH3 correlated with clinical out-
comes.33,34 Thus, plasma DNA-citH3 levels were signifi-
cantly higher in septic patients (n=58) than in non-septic
patients (n=23) (P<0.001). Furthermore, DNA-citH3 levels
were significantly higher in patients in whom treatment
failed or cardiovascular events occurred (n=18) than in the
rest of the patients (n=63) (P=0.028) (Online Supplementary
Table S2).
Interestingly, we observed significant differences
between the occurrence of cardiovascular complications
and rs2431697 genotype. As shown in Table 1, 30 of the
259 patients suffered from cardiovascular events when
hospitalized and 29 of them were carriers of the T allele
(relative risk [RR]=9.61, [95% CI]: 95% confidence inter-
val: 1.28-72.15, P=0.008). The risk of cardiovascular
events remained significantly higher for CT+TT patients
30 days after hospitalization (RR=2.85, 95% CI: 0.97-
8.37, P=0.049) (Table 1). In addition, 21.4% of the carriers
of the T allele developed a cardiovascular event and failed
to respond to therapy (RR=2.89, 95% CI: 1.09-7.66,
P=0.027) (Table 1). Finally, among patients with the high-
est DNA-citH3 plasma levels (≥0.406 OD units) we found
a 3-fold higher frequency of T carriers individuals (30%)
compared to CC homozygotes (9.5%; P=0.061) (Table 2).
Discussion
In the last years, the functional versatility of neu-
trophils has moved towards a fascinating area of research
in which the inflammatory capacity of these cells is tight-
ly linked to the development of cardiovascular diseases.35
On the other hand, the pathophysiological role of NET in
thrombogenesis is now firmly established.36 In this
process, known as immunothrombosis, the mechanisms
leading to NETosis differ depending on the triggering
stimulus.7 Identifying key regulators of NETosis37 is a
challenge to further contribute to the development of
anti-thrombotic therapeutic tools that would not affect
the essential role of NET fighting germs. In this work, we
show that miR-146a, a well-known molecular brake to
the NF-κB pathway, underlies NETosis-mediated throm-
bosis after both sterile and non-sterile stimulation. 
First, we demonstrated that sterile inflammation in a
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Table 1. Relationship between hospital cardiovascular complications
and rs2431697 genotype in patients with community-acquired pneu-
monia (n=259).
                                   CC                        CT+TT                  P
                                 N=58                     N=201         RR (95% CI)
CVE, N                               1                                  29                      0.008
(%)                                 (1.7)                           (14.4)        9.61 (1.28-72.15)
TF, N                                   4                                  22                      0.366
(%)                                 (6.9)                           (10.9)                       -
CVE+TF, N                        5                                  43                      0.027
(%)                                 (8.6)                           (21.4)         2.89 (1.09-7.66)
CVE-30, N                         4                                  35                      0.049
(%)                                 (6.9)                           (17.4)         2.85 (0.97-8.37)
RR: relative risk; 95% CI: 95% confidence interval; CVE: cardiovascular events during
hospitalization, including pulmonary thromboembolism; TF: treatment failure during
hospitalization; CVE+TF: occurrence of cardiovascular event and/or treatment failure;
CVE-30: cardiovascular events 30 days after hospitalization.
Table 2. rs2431697 genotype frequencies according to DNA-citrulli-
nated H3 plasma levels in patients with community-acquired pneumo-
nia.
                         DNA-citH3 < 4Q         DNA-citH3 > 4Q                P*
CC, N                                19                                      2
(%)                                (90.5)                               (9.5)                                 
CT+TT, N                         42                                     18                               0.061
(%)                                (70.0)                              (30.0)                                
4Q indicates 4th quartile (≥0.406 optical density units). Measurements were performed
in a total of 81 patients (OD≥0.200). *ƛ2 test.
model of miR-146a deficiency in the hematopoietic line-
age caused greater NET formation. However, we previ-
ously showed that miR-146a deficiency in the
hematopoietic lineage had no effect on atherogenesis
after 8 weeks of an atherogenic diet.26 Here, our results
suggest that miR-146a deficiency may participate in
thrombosis rather than in atherogenesis, through
NETosis. This hypothesis is in accord with results pub-
lished by Franck et al. demonstrating that NETosis does
not alter atherosclerotic plaque formation but rather
increases thrombosis in a model of plaque erosion.38
Supporting this hypothesis, previous reports have shown
that thrombosis induction increases NET deposition.39,40
Consistently, when arterial thrombosis was induced by
FeCl3 injury, we observed an increased generation of NET
in the thrombi of miR-146a-/-mice compared to WT mice,
with a shorter time to vessel occlusion. The abolition of
thrombosis by removal of NET with DNAse I in miR-
146a-/-and WT mice, further supports the essential role of
miR-146a in NET production. In this sense, Massberg et
al. also found in a murine model of FeCl3 injury that the
inhibition of NET components, by infusion of anti-H2A-
H2B-DNA antibody, prolonged the occlusion time and
generated low stability thrombi in the carotid.39
Next, we created a non-sterile model of inflammation
by LPS injection into miR-146a-/- mice. Indeed, miR-146a-/-
mice exhibit hyperreactivity to LPS, with an exacerbated
inflammatory response, demonstrating miR-146a as a
regulator of autoimmunity, myeloproliferation, and can-
cer.23 Our results showed that miR-146a deficiency pro-
vokes higher rates of NETosis in LPS-challenged mice. Of
note, no differences were found in the capacity of phago-
cytosis between miR-146a-/- and WT neutrophils in vitro
after LPS challenge (data not shown). In addition, miR-146a
deficiency promotes a pro-coagulant phenotype with
increased levels of thrombin-antithrombin complexes and
ROS production and regulates the extent of organ dam-
age following infection, as miR-146a-/- mice developed
greater lung damage than did WT mice. Although the use
of murine models is considered useful for understanding
the pathophysiology of sepsis, there are notable differ-
ences between these models and sepsis in humans.41 We
therefore examined NETosis markers and their relation-
ship with thrombosis in CAP patients. Plasma NETosis
markers correlated with the incidence of sepsis in accor-
dance with previously reported data,42 further supporting
the concept that sepsis is a relevant model for investigat-
ing the role of NET in humans. Interestingly, we found a
correlation between NETosis and thrombotic complica-
tions in CAP patients. Our group has previously
described that the miR-SNP rs2431697 of MIR146A is
associated with an increased risk of cardiovascular events
in patients with atrial fibrillation.24 Here, we have verified
the role of rs2431697 genotype in cardiovascular events in
patients with CAP. Supporting our findings, Xie et al.
reported that activation of miR-146a expression
decreased markers of myocardial injury in rats treated
with LPS.43 In addition, the injection of miR-146a has
been described to play a protective role in the cardiac dys-
function induced by sepsis in a murine model, with
longer survival of the mice.44 Results from our cohort indi-
cate that NETosis could be a functional path by which
miR-146a levels lead to thrombosis in septic patients. Of
note, we found that among patients with higher levels of
NETosis markers, carriers of the T allele were 3-fold more
frequent than CC patients. The concept of sepsis and car-
diovascular diseases sharing a common pathophysiology
has been explored recently.45 Common gene signaling
pathways for both sepsis and cardiovascular diseases
were investigated and genetic variations in miR-146a tar-
gets such as IL6 or IRAK1 were found to be shared in
patients with both diseases.45 Although the etiology of
sepsis and cardiovascular disease is not identical, the two
conditions share the same end-points of inflammation,
coagulation, and endothelial activation.46,47 Overall our
results demonstrate that miR-146a is involved in throm-
bogenesis of two diseases with cardiovascular events,
atrial fibrillation and sepsis, a priori in two different mod-
els. Accordingly, miR-146a may be yet another regulator
of immunothrombosis.
The mechanisms leading to the increased NET forma-
tion by miR-146a are still elusive. Interestingly, pro-
inflammatory activity of neutrophils has been shown to
correlate positively with aging.30 Aged neutrophils are the
A.B. Arroyo et al.
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Figure 5. miR-146a plays a relevant role in thrombo-inflammation after sterile
and non-sterile stresses. Low miR-146a levels promote an aging phenotype in
neutrophils (CD62low CD11bhigh Cxcr4high Tlr4high) which primes these cells. Upon
sterile or non-sterile stimuli, primed neutrophils would be more prone to
NETosis leading to a thrombo-inflammatory process. MiR-146a: microRNA-
146a; LPS: lipopolysaccharide; CAP: community-acquired pneumonia.
first line of defense in the context of acute inflammation
since they do not return to the bone marrow, arrive first
at the inflammatory tissues and infiltrate them in a
TLR4/CD11b-dependent manner.48 Thus, we investigated
neutrophil phenotype in miR-146a-/- mice in order to
explain the greater NET formation observed in our differ-
ent models. We found that miR-146a-/- resting neutrophils
have an aging phenotype CD62Llow CD11bhigh Cxcr4high,
and a lower expression of Cxcr1.1
Thus, we speculate that miR-146a deficiency could act
as a priming effector on resting neutrophils so that, under
any inflammatory stimulus, (sterile or non-sterile) these
cells would reach higher activation rates than WT neu-
trophils. Our results show that Tlr4, which is a validated
target of miR-146a, is overexpressed in aged miR-146a-/-
neutrophils in comparison with WT ones. One possible
explanation for this finding may be that the deficiency of
miR-146a favors a higher deregulation of the Tlr4/Nf-κB
axis in aged neutrophils than in non-aged ones. Thus, this
hypothesis would also explain in part why circulating
aged neutrophils are more prone to make NET, a previous
indolent signal being necessary to prime these cells.49,50
Indeed, it has been shown that Tlr4-/- mice or germ-free
mice have less aged neutrophils than WT littermates.30
In accord with our hypothesis, we observed higher
ROS levels and oxygen consumption rate in neutrophils
from miR146-/- mice than WT mice, which may further
suggest a primed status in miR-146a-/- neutrophils.
Importantly, the aging process is promoted in large part
by ROS that produce cellular damage.51 ROS (mainly pro-
duced by NADPH oxidase) are also crucial to initiate the
process of NET formation.52
There are a few limitations in this study. First, for the in
vivo inflammation models, we did not use a complex
marker such as a granulocytic enzyme bound to DNA to
measure NET. NET were quantified using cfDNA, NE,
and citH3 for the LPS model and tissue immunofluores-
cence in the atherosclerotic model. Thus, we cannot rule
out that part of the cfDNA and NE measured in plasma
was due to neutrophil secretion or to apoptotic processes.
Another point is that our study was performed in full
miR-146a-/- mice or BM transplanted mice. Given the
interplay of other cells with neutrophils to promote
NETosis, in particular platelets,9,10 it would be of interest
in future studies to dissect the mechanisms implicating
miR-146a in the formation of NET using conditional
models of miR-146a deficiency.
In summary, our results demonstrate that miR-146a
deficiency promotes an aged neutrophil phenotype prim-
ing these cells for activation. Upon both sterile and non-
sterile stimuli, such sensitized neutrophils are more prone
to form NET, leading to thrombosis when physiological
control is overwhelmed (Figure 5). Indeed, we demon-
strate this hypothesis in a human disease, sepsis, in
which patients with low miR-146a levels due to
rs2431697 have increased plasma NET markers and a
higher risk of cardiovascular events. These data not only
strengthen the proposed interconnection between inflam-
mation and thrombosis but also open new perspectives
for the development of therapeutic tools against NETosis
in different thrombo-inflammatory contexts.
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